Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Marincek

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|March 21, 2015
Towards tailored radiopeptide therapyPiotr Radojewski, Rebecca Dumont, Nicolas Marincek, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 2, 2016
Reply: Somatostatin Receptor-Targeted Radiopeptide Therapy in Patients with Progressive Unresectable MeningiomaPiotr Radojewski, Rebecca A Dumont, Nicolas Marincek, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 17, 2015
Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trialNicolas Marincek, Piotr Radojewski, Rebecca A Dumont, et al.
Biomaterials|May 21, 2014
Indium-111 labeled gold nanoparticles for in-vivo molecular targetingQuinn K T Ng, Cristina I Olariu, Marcus Yaffee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2011
Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancersAnna Imhof, Philippe Brunner, Nicolas Marincek, et al.
American Journal of Nuclear Medicine and Molecular Imaging|January 28, 2015
Survival after somatostatin based radiopeptide therapy with (90)Y-DOTATOC vs. (90)Y-DOTATOC plus (177)Lu-DOTATOC in metastasized gastrinomaRebecca A Dumont, Daniela Seiler, Nicolas Marincek, et al.
Journal of Translational Medicine|January 17, 2013
Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation studyNicolas Marincek, Ann-Catherine Jörg, Philippe Brunner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 11, 2017
Reply: Diabetes Mellitus and Its Effects on All-Cause Mortality After Radiopeptide Therapy for Neuroendocrine Tumors: Methodologic IssuesMaria Umlauft, Piotr Radojewski, Petar-Marko Spanjol, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 17, 2016
Diabetes Mellitus and Its Effects on All-Cause Mortality After Radiopeptide Therapy for Neuroendocrine TumorsMaria Umlauft, Piotr Radojewski, Petar-Marko Spanjol, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 2, 2016
Upregulation of Key Molecules for Targeted Imaging and TherapyVincent F Taelman, Piotr Radojewski, Nicolas Marincek, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
European Journal of Nuclear Medicine and Molecular Imaging|March 21, 2015
Towards tailored radiopeptide therapyPiotr Radojewski, Rebecca Dumont, Nicolas Marincek, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 2, 2016
Reply: Somatostatin Receptor-Targeted Radiopeptide Therapy in Patients with Progressive Unresectable MeningiomaPiotr Radojewski, Rebecca A Dumont, Nicolas Marincek, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 17, 2015
Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trialNicolas Marincek, Piotr Radojewski, Rebecca A Dumont, et al.
Biomaterials|May 21, 2014
Indium-111 labeled gold nanoparticles for in-vivo molecular targetingQuinn K T Ng, Cristina I Olariu, Marcus Yaffee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2011
Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancersAnna Imhof, Philippe Brunner, Nicolas Marincek, et al.
American Journal of Nuclear Medicine and Molecular Imaging|January 28, 2015
Survival after somatostatin based radiopeptide therapy with (90)Y-DOTATOC vs. (90)Y-DOTATOC plus (177)Lu-DOTATOC in metastasized gastrinomaRebecca A Dumont, Daniela Seiler, Nicolas Marincek, et al.
Journal of Translational Medicine|January 17, 2013
Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation studyNicolas Marincek, Ann-Catherine Jörg, Philippe Brunner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 11, 2017
Reply: Diabetes Mellitus and Its Effects on All-Cause Mortality After Radiopeptide Therapy for Neuroendocrine Tumors: Methodologic IssuesMaria Umlauft, Piotr Radojewski, Petar-Marko Spanjol, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 17, 2016
Diabetes Mellitus and Its Effects on All-Cause Mortality After Radiopeptide Therapy for Neuroendocrine TumorsMaria Umlauft, Piotr Radojewski, Petar-Marko Spanjol, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 2, 2016
Upregulation of Key Molecules for Targeted Imaging and TherapyVincent F Taelman, Piotr Radojewski, Nicolas Marincek, et al.
Pageof 2